Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!

Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!

Apply now for the second Edition of the PRECISEU Best Practice Recognition!

The PRECISEU Best Practice Recognition is more than a contest—it is a movement to accelerate the future of personalised medicine across Europe. Born from the PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope (PRECISEU) programme, this visionary initiative shines a spotlight on pioneers who are translating cutting-edge science into realworld care—especially through the innovative and responsible use of health data. With ambitious purpose it celebrates exemplary practices that not only push the boundaries of what’s possible but also make these breakthroughs accessible, equitable, and impactful for all. This recognition is a catalyst for transformation—bridging science and society, innovation and implementation, vision and care. It calls upon researchers, entrepreneurs, institutions, and citizens alike to lead with purpose, collaborate boldly, and ensure that life-changing therapies reach every patient, everywhere—fast and fair. PRECISEU Best Practice Recognition honours not just innovation, but the courage to act, the will to include, and the power to change lives.

The call is now open for the second Edition

We offer three more sessions where we explain how to apply:

Info session 1: 12 December 2025, 1:30 – 2:30 pm – register here

Info session 2: 8 January 2026  1:30 – 2:30 pm – register here

Info session 3: 6. February 2026, 1:30 – 2:30 pm – register here

Find a preview to the questionnaire to be filed here. 

Call deadline March 1st 2026. Apply here. 

 Useful links

register now

Our latest News

discover more
China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]

aimed analytics GmbH highlighted in deutsche-startups.de

aimed analytics GmbH highlighted in deutsche-startups.de

5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp